8756 Telemonitoring Use For Uncontrolled Type 2 Diabetes Management: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials
Authors: Kelly Francinny Alves , Leite Marianna G H S J , Sudo Renan Yuji Ura , de Moraes Francisco Cezar Aquino , Morbach Victória , Pasqualotto Eric , da Silva Izael Pereira , Barros Maria Luísa Siegloch , Lima Pedro Lucas Gomes , de Oliveira Macena Lôbo Artur , Pessôa Felipe Dircêu Dantas Leite , Cardoso Jorge Henrique Cavalcanti Orestes , Lopes Lucca Moreira , Jardine Matheus Budahazi , Lima Micael Porto Portela , De Almeida Artur Menegaz , Andrade Italo Barros , Souza Maria Eduarda Cavalcanti 
Published: October 2024

Disclosure: F.A. Kelly: None. M.G. Leite: None. R.Y. Ura Sudo: None. F.A. Moraes: None. V. Morbach: None. E. Pasqualotto: None. I.P. da Silva: None. M.S. Barros: None. P.G. Lima: None. A.D. Lôbo: None. F.D. Pessôa: None. J.C. Cardoso: None. L.M. Lopes: None. M.B. Jardine: None. M.P. Lima: None. A.M. De Almeida: None. I.B. Andrade: None. M. Cavalcanti Souza: None.

In the dynamic landscape of healthcare, the integration of telemedicine is reshaping how chronic conditions, such as type 2 diabetes (T2D), are managed. As we delve into the evolving paradigm of healthcare delivery, there is a growing interest in understanding the potential of telemedicine compared to traditional or "usual care" models for T2D. The prevalence of T2D globally underscores the need for innovative, patient-centric solutions that go beyond geographical constraints. Telemedicine, with its promise of real-time monitoring, improved patient engagement, and personalized care, stands out as a potential game-changer in the pursuit of optimal diabetes management. We aimed to perform a meta-analysis of the strategic redesign of healthcare services, harnessing information and communication technology (ICT) to enhance T2D management and glycemic control, providing timely interventions, and improving patient outcomes. This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Review (PRISMA) guidelines. PubMed, Web of Science, Scopus, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing ICT interventions to usual care for T2D management. A random-effects model was used to calculate the mean differences (MDs) with 95% confidence intervals (CIs). Heterogeneity was evaluated with I² statistics. Statistical analysis was performed with Software R, version 4.3.1.A total of 46 studies comprising 26,129 patients were included, of whom 16,443 were randomized to ICT and 9,686 to usual care. Compared with usual care, ICT significantly reduced HbA1c (MD -0.36%; 95% CI -0.49, -0.23; p&lt;0.001; I²=74%) and fast blood glucose (FBG) (MD -0.37 mg/dL; 95% CI -0.58, -0.15; p&lt;0.001; I²=47%). There was no significant difference between groups for body mass index (MD -0.17 Kg/m²; 95% CI -0.47, 0.13; p=0.274; I²=89%), total cholesterol (MD -0.06 mmol/L; 95% CI -0.18, 0.05; p=0.287; I²=68%), low-density lipoprotein cholesterol (LDL-c) (MD -0.37 mmol/L; 95% CI -/ 0.93, 0.19; p=0.193, I²=97%), high-density lipoprotein cholesterol (HDL-c) (MD -0.29 mg/dL; 95% CI -0.78, 0.20; p=0.249; I²=92%), triglyceride (MD 0.02 mmol/L; 95% CI -0.33, 0.37; p=0.896; I²=99%).In this meta-analysis of RCTs of patients with T2D, ICT was associated with a significant reduction in HbA1c and FBG, compared with usual care.

Presentation: 6/1/2024